Blood Cancers: Leukaemia, Lymphoma and Myeloma

Blood cancers are several biologically distinct diseases affecting blood forming cells, lymphocytes or plasma cells. Leukaemia, lymphoma and myeloma can behave very differently. Some require emergency treatment, while others can be monitored safely for years before treatment becomes necessary.

What blood cancers are Blood cancers arise from cells involved in producing blood or supporting immune function. The three main families covered here are leukaemia, lymphoma and myeloma. Leukaemia usually begins in blood forming tissue within the bone marrow and often affects circulating blood cells. Lymphoma begins in lymphocytes, commonly within lymph nodes or other lymphatic tissue. Myeloma develops from plasma cells within the bone marrow. One label covers many diseases Blood cancer is an umbrella term rather than one diagnosis. Each family contains several subtypes with different genetic changes, growth rates and treatment responses. Some conditions progress over days or weeks. Others remain stable without treatment for years. Accurate classification is essential because treatment suitable for one blood cancer may not help another. How normal blood cells are made Bone marrow is the soft tissue inside many bones. It contains stem cells that develop into red blood cells, white blood cells and platelets. Red blood cells carry oxygen. White blood cells contribute to immune defence. Platelets help control bleeding after blood vessel injury. Cancerous cells can crowd out normal marrow production and disrupt one or several of these functions. What marrow failure means Marrow failure means that the bone marrow cannot produce enough normal blood cells. Low red cell numbers cause anaemia, fatigue, pallor and breathlessness. Low functional white cell numbers increase infection risk. Low platelets can cause bruising, petechiae and bleeding. This pattern is particularly important in acute leukaemia, but it can occur in other advanced blood cancers. Leukaemia Leukaemia is cancer involving blood forming cells, usually within the bone marrow. Abnormal cells can enter the bloodstream and sometimes infiltrate the spleen, liver, lymph nodes or other tissues. The white cell count may be high, normal or low. A high white cell count does not automatically mean leukaemia, and a normal total count does not exclude it. The cell type, maturity and genetic findings determine the exact diagnosis. Acute and chronic leukaemia The words acute and chronic describe biological behaviour rather than how severe symptoms feel on one day. Acute leukaemias involve rapidly accumulating immature cells called blasts. They commonly impair normal blood cell production over days or weeks. Chronic leukaemias usually involve more mature looking cells and often progress more slowly. A chronic leukaemia can still cause serious complications or transform into a faster phase. Acute myeloid leukaemia Acute myeloid leukaemia, usually called AML, develops from myeloid blood forming cells. It is more common in older adults but can occur at any age. Symptoms often result from anaemia, infection and low platelets. AML contains several genetic and molecular subtypes that affect treatment and prognosis. Treatment usually needs to begin quickly after specialist confirmation. Acute lymphoblastic leukaemia Acute lymphoblastic leukaemia, usually called ALL, develops from immature lymphoid cells. It is the most common childhood leukaemia but also occurs in adults. ALL may involve B cell or T cell precursors. It can affect lymph nodes, the spleen, the central nervous system or the area within the chest. Treatment is prolonged and may combine chemotherapy, steroids, targeted medicines and immunotherapy. Acute leukaemia is a haematological emergency Acute leukaemia can cause rapid marrow failure, severe infection or dangerous bleeding. Some people develop very high numbers of abnormal cells that interfere with blood flow through small vessels. Cell breakdown can disturb potassium, phosphate, calcium and uric acid levels. A blood count or blood film suggesting acute leukaemia therefore requires same day emergency haematology assessment. This is different from waiting for a routine suspected cancer appointment. Very urgent blood testing before diagnosis NICE recommends a very urgent full blood count for adults with unexplained pallor, persistent fatigue or fever. The same applies to persistent or recurrent infection, generalised lymph node enlargement, bruising, bleeding or petechiae. Unexplained enlargement of both the liver and spleen also warrants very urgent testing. Very urgent means that the investigation should occur within 48 hours. The result determines whether same day specialist action is required. Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia, usually called CLL, affects mature B lymphocytes. It often develops slowly and may be discovered incidentally on a routine blood count. Some people remain well without treatment for many years. Others develop enlarging lymph nodes, recurrent infections, anaemia, low platelets or systemic symptoms. Treatment begins when the disease causes defined clinical problems rather than because abnormal cells are present alone. Chronic myeloid leukaemia Chronic myeloid leukaemia, usually called CML, develops from a myeloid stem cell. Most cases contain the BCR ABL1 fusion gene, also called the Philadelphia chromosome abnormality. This change produces an overactive growth signal. Targeted tyrosine kinase inhibitor medicines can control this signal in many people. Untreated CML can progress from a chronic phase into accelerated or blast phase disease. Other leukaemias Other leukaemia families include hairy cell leukaemia and rarer chronic or acute subtypes. Myelodysplastic syndromes and myeloproliferative neoplasms also arise from marrow cells but have distinct classifications. Some can progress to acute leukaemia. A broad label such as abnormal white cells is therefore not a complete diagnosis. Lymphoma Lymphoma is cancer of lymphocytes, which are white blood cells involved in immune defence. It commonly begins within lymph nodes but can arise in almost any organ. The spleen, bone marrow, skin, stomach, bowel, brain and other tissues can be affected. Lymphoma is divided first into Hodgkin lymphoma and non Hodgkin lymphoma. The lymphatic system The lymphatic system contains lymph vessels, lymph nodes, the spleen and other immune tissues. Lymph nodes filter lymphatic fluid and support immune responses. Normal nodes commonly enlarge during infection and then reduce again. A persistent unexplained node requires assessment because infection, inflammatory disease and cancer can produce similar swelling. Hodgkin lymphoma Hodgkin lymphoma is defined by characteristic malignant cells within a particular tissue pattern. Classical Hodgkin lymphoma usually contains Reed Sternberg cells. It commonly presents with painless enlargement of lymph nodes in the neck or chest. Many people are cured using chemotherapy, sometimes combined with radiotherapy. A rarer form called nodular lymphocyte predominant B cell lymphoma behaves differently and can sometimes be monitored initially. Non Hodgkin lymphoma Non Hodgkin lymphoma, usually called NHL, includes many B cell, T cell and natural killer cell cancers. Examples include follicular lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma and Burkitt lymphoma. The category ranges from indolent disease to cancers that double rapidly and need immediate treatment. The exact tissue subtype matters more than the broad NHL label alone. Indolent lymphoma Indolent lymphomas usually grow slowly. A person can have widespread disease without needing immediate treatment when it is causing no clinical harm. Examples include many follicular and marginal zone lymphomas. Treatment can control disease for prolonged periods, although some indolent lymphomas are not usually cured when widespread. A slow lymphoma can occasionally transform into a more aggressive type. Aggressive lymphoma Aggressive lymphomas grow quickly and usually require prompt treatment. Diffuse large B cell lymphoma is a common example. Burkitt lymphoma grows particularly rapidly and requires intensive specialist therapy. Fast growth can make these diseases dangerous, but it can also make them highly sensitive to chemotherapy. Some aggressive lymphomas remain curable even when several body areas are involved. Lymphadenopathy Lymphadenopathy means enlarged lymph nodes. Lymphoma nodes are often painless, firm and persistent, but these features are not diagnostic. Tender nodes commonly occur with infection, although lymphoma nodes can occasionally be painful. Nodes in the neck, armpit or groin are easier to notice. Chest or abdominal lymph nodes may cause symptoms without being palpable. When lymph nodes need assessment A node that remains enlarged, increases in size or has no clear explanation requires review. Generalised lymphadenopathy means that nodes are enlarged in more than one region. Unexplained lymphadenopathy or splenic enlargement in an adult can justify suspected cancer referral for lymphoma. Fever, night sweats, weight loss, itching or breathlessness increase concern. A referral means lymphoma needs to be excluded, not that it is already confirmed. B symptoms B symptoms are particular systemic features used when assessing lymphoma. They include unexplained fever, drenching night sweats and significant unintentional weight loss. Night sweats means clothing or bedding becomes soaked, not simply feeling warm during sleep. These symptoms affect lymphoma staging and prognosis in some subtypes. They also occur with infection, hormonal change and other illnesses. Hodgkin and non Hodgkin are not stages Hodgkin lymphoma and non Hodgkin lymphoma are separate biological families. One is not an earlier or later version of the other. Each family contains its own subtypes, stages and risk groups. Treatment cannot be chosen from the Hodgkin or non Hodgkin label without adequate tissue classification. Myeloma Myeloma is cancer of plasma cells within the bone marrow. Plasma cells normally develop from B lymphocytes and produce antibodies. Cancerous plasma cells multiply as one clone and can produce an abnormal antibody or antibody fragment. Myeloma can damage bones, impair kidney function, suppress normal blood production and weaken immunity. Paraprotein A paraprotein is an abnormal antibody produced by one clone of plasma cells or related lymphocytes. It can be detected using serum protein electrophoresis and related tests. Some myelomas produce only free light chains rather than a complete antibody. A paraprotein does not automatically mean active myeloma. It can occur in monoclonal gammopathy of undetermined significance and other conditions. MGUS Monoclonal gammopathy of undetermined significance is usually shortened to MGUS. It involves a small abnormal plasma cell clone without myeloma related organ damage. MGUS is not active myeloma and does not require anticancer treatment. It carries a small continuing risk of progression, so selected people receive monitoring. Smouldering myeloma Smouldering myeloma lies between MGUS and active myeloma. There are more abnormal plasma cells or a larger paraprotein burden, but no myeloma defining organ damage or biomarker threshold requiring treatment. It is monitored closely because progression risk is higher than with MGUS. Watchful monitoring is deliberate management rather than neglect. Active myeloma Active myeloma is diagnosed when the plasma cell cancer is causing defined damage or meets validated high risk biomarker criteria. Treatment should not be started from a paraprotein result alone. The specialist combines marrow findings, blood and urine tests, imaging and clinical features. Bone damage in myeloma Myeloma disrupts the normal balance between bone breakdown and rebuilding. This can create areas of bone loss called lytic lesions. Persistent pain often affects the back, ribs, hips or shoulders. Bones can fracture after minor force or ordinary movement. Sudden weakness or loss of continence with back pain can indicate spinal cord compression. Anaemia in myeloma Abnormal plasma cells can crowd out normal red cell production. Kidney disease and inflammation can also contribute to anaemia. Possible symptoms include fatigue, pallor, breathlessness and reduced exercise tolerance. Anaemia has many possible causes and does not diagnose myeloma alone. Kidney injury in myeloma Abnormal free light chains can damage kidney tubules. High calcium, dehydration, infection and some medicines can worsen kidney function. Reduced urine, nausea, swelling, confusion or severe weakness can accompany significant kidney injury. Myeloma with acute kidney injury requires urgent specialist management. Anti inflammatory painkillers can sometimes worsen kidney function and should be discussed with the clinical team. High calcium Bone breakdown can release excessive calcium into the bloodstream. Hypercalcaemia can cause thirst, frequent urination, constipation, nausea and muscle weakness. More severe cases cause dehydration, drowsiness, confusion or abnormal heart rhythms. Significant symptomatic hypercalcaemia requires urgent hospital treatment. Infection in myeloma Although myeloma cells produce antibody protein, it does not provide normal broad protection. Production of useful antibodies can fall. Myeloma and its treatments therefore increase infection risk. Persistent, recurrent or severe infections require assessment and may need preventive treatment. Symptoms overlap across blood cancers Fatigue, weight loss, fever and infection are non specific symptoms. Bruising can result from medicines, trauma, liver disease or non cancerous platelet problems. Lymph nodes commonly enlarge during infection. Bone pain is usually musculoskeletal rather than myeloma. The pattern, persistence, examination and laboratory results determine the next step. The full blood count A full blood count measures red cells, white cells and platelets. It can identify anaemia, low platelets and abnormal white cell patterns. It does not diagnose the cause by itself. Acute leukaemia can produce high, normal or low white cell counts. Lymphoma and early myeloma can occur with a relatively normal full blood count. The white cell differential The differential count separates white cells into major categories. It can show lymphocytosis, neutropenia or other abnormal patterns. An automated count cannot always identify the exact abnormal cell. Laboratory review and a blood film may be needed. The blood film A blood film spreads a thin layer of blood on a glass slide for microscopic examination. It allows trained scientists and haematologists to assess cell size, shape, maturity and distribution. Blasts can raise immediate concern for acute leukaemia. Other film patterns can suggest chronic leukaemia, infection, marrow stress or a non cancerous blood disorder. A blood film provides a clue and classification evidence rather than the complete diagnosis alone. Flow cytometry Flow cytometry identifies proteins on and within individual cells. It can establish whether abnormal cells belong to a myeloid, B cell or T cell lineage. It is central to classifying many leukaemias and lymphomas. The result is interpreted with morphology, genetics and clinical information. Cytogenetic and molecular testing Blood cancers are increasingly defined by chromosome and gene changes. These tests can confirm a subtype, estimate risk and identify a treatment target. Examples include BCR ABL1 in CML and several molecular groups within AML and ALL. Most changes detected in cancer cells are acquired rather than inherited. Separate germline testing is needed when an inherited predisposition is suspected. Bone marrow aspiration A bone marrow aspirate removes liquid marrow, usually from the back of the pelvis. The sample shows the proportions and appearances of marrow cells. It supports flow cytometry, chromosome testing and molecular analysis. Local anaesthetic reduces skin and bone surface pain, although drawing out the marrow can feel briefly uncomfortable. Bone marrow trephine biopsy A trephine biopsy removes a narrow core of marrow and bone. It preserves the architecture and shows how cells are distributed within the marrow. An aspirate and trephine provide complementary information. Bone marrow examination is central to diagnosing and classifying acute leukaemia and myeloma. It is used selectively for lymphoma staging or when marrow involvement is clinically important. Lymph node biopsy Lymphoma usually requires a biopsy of an affected lymph node or extranodal mass. Removing an entire node is often preferred for suspected non Hodgkin lymphoma because its architecture helps classification. A large core needle biopsy may be used when surgery carries greater risk or the node is difficult to reach. A small fine needle cell sample may not provide enough tissue to classify lymphoma reliably. Why lymph node architecture matters Lymphoma classification depends on which cells are present and how they are arranged. Pathologists assess cell appearance, tissue pattern, protein markers and genetic changes. This allows distinction between Hodgkin lymphoma and numerous non Hodgkin subtypes. Treatment should not begin from imaging or node size alone unless an emergency makes immediate action necessary. Myeloma blood and urine tests Assessment can include a full blood count, kidney function, calcium and inflammatory markers. Serum protein electrophoresis looks for a paraprotein. Serum free light chain testing measures unbound antibody components. Urine testing can identify light chains and assess kidney effects. No one test should be used alone to exclude myeloma. Myeloma imaging Modern imaging looks for bone and soft tissue disease throughout the body. Whole body MRI and low dose whole body CT can detect lesions not visible on an ordinary skeletal X ray. PET CT is useful in selected situations. Imaging choice depends on availability, symptoms and the clinical question. Lymphoma staging Lymphoma is commonly staged from I to IV according to the areas involved. Stage I affects one lymph node region or one localised extranodal site. Stage II affects more than one region on the same side of the diaphragm. Stage III involves regions on both sides of the diaphragm. Stage IV includes widespread involvement of organs such as bone marrow or liver. Stage IV lymphoma is not automatically terminal Lymphoma staging differs from staging in many solid cancers. Some stage IV aggressive lymphomas remain curable with systemic treatment. Some widespread indolent lymphomas require no immediate treatment. Subtype, symptoms, tumour bulk, blood results and treatment response can matter as much as anatomical stage. Leukaemia is not staged using TNM Leukaemia is a dispersed blood and marrow disease rather than one solid primary tumour. It is therefore not staged through tumour, node and metastasis categories. Clinicians use the exact subtype, genetic risk, blood and marrow burden, organ involvement and treatment response. Chronic leukaemias may use disease specific staging or phase systems. Myeloma staging Myeloma staging uses laboratory and genetic features rather than the location of one primary mass. Measures can include beta 2 microglobulin, albumin, lactate dehydrogenase and high risk chromosome findings. Stage contributes to prognosis but does not determine treatment alone. Age, frailty, kidney function and transplant suitability are also important. Watch and wait management Watch and wait means planned monitoring without immediate anticancer treatment. It is appropriate for selected indolent lymphomas, early asymptomatic CLL and smouldering plasma cell disorders. Monitoring can include symptoms, examination, blood counts and other disease specific tests. Treatment begins when defined progression or clinical problems appear. Watch and wait is not doing nothing. Why treatment can safely wait Immediate treatment does not improve outcomes for every symptom free indolent blood cancer. Starting too early can expose someone to infection, organ toxicity and treatment resistance without useful benefit. Deferring therapy preserves treatment options until they are needed. New symptoms should be reported rather than waiting for the next scheduled appointment. Treating acute leukaemia Acute leukaemia treatment aims to produce remission by removing detectable leukaemia cells. Intensive chemotherapy is appropriate for many fit people. Lower intensity combinations may suit people who cannot tolerate intensive treatment. Targeted medicines or immunotherapies are added when the subtype has a relevant biological feature. ALL treatment also includes protection or treatment directed towards the central nervous system. Induction and consolidation Induction is the first intensive phase intended to achieve remission. Consolidation aims to remove remaining disease and reduce relapse risk. ALL often includes further maintenance treatment over a longer period. The exact phases and medicines differ greatly between AML, ALL and their subtypes. Remission is not always the same as cure Remission means that standard tests no longer detect active disease at the previous level. Small numbers of cancer cells can remain below ordinary microscopic detection. Minimal or measurable residual disease testing uses sensitive methods to look for these cells. Residual disease results can influence further treatment or transplantation decisions. Treating chronic leukaemia CLL treatment commonly uses targeted oral medicines, antibody treatment or selected chemotherapy combinations. Treatment is delayed until symptoms, progressive marrow failure or other defined indications appear. CML is usually treated with a tyrosine kinase inhibitor targeting BCR ABL1. Regular molecular testing shows how deeply the abnormal clone is responding. Treating Hodgkin lymphoma Classical Hodgkin lymphoma is usually treated with combination chemotherapy. Radiotherapy is added in selected early, bulky or residual disease settings. Treatment aims for cure in most newly diagnosed people. Relapsed disease may require different chemotherapy, targeted treatment, immunotherapy or stem cell transplantation. Treating non Hodgkin lymphoma Treatment depends on the exact subtype and whether it is indolent or aggressive. Options include antibody treatment, chemotherapy, targeted medicines, immunotherapy and radiotherapy. Localised indolent lymphoma may be treated with radiotherapy. Aggressive lymphoma usually requires prompt systemic treatment. Selected relapsed B cell lymphomas can be treated with CAR T cell therapy. Treating myeloma Active myeloma is treated with combinations of medicines that attack plasma cells through different mechanisms. These can include targeted medicines, immunomodulatory medicines, antibodies, steroids and chemotherapy. Treatment aims to control disease, reverse organ damage and produce the deepest safe response. Myeloma is not usually curable with current standard treatment, but it can often be controlled through several treatment lines. Autologous stem cell transplantation Autologous transplantation uses the person's own previously collected stem cells. High dose chemotherapy treats the cancer, and the stored cells then restore marrow production. This approach is commonly used for suitable people with myeloma and some relapsed lymphomas. The transplant itself does not directly attack the cancer. It allows recovery after otherwise damaging high dose treatment. Allogeneic stem cell transplantation Allogeneic transplantation uses blood forming stem cells from a donor. The donor immune system can attack remaining cancer through a graft versus leukaemia or lymphoma effect. This can offer long term disease control or cure in selected high risk leukaemias and other cancers. It carries substantial risks, including infection, organ injury and graft versus host disease. It is therefore offered only after careful specialist assessment. Stem cell transplantation is not routine for everyone Transplant suitability depends on cancer subtype, risk, response, age, health and donor availability. Many people are cured or controlled without transplantation. Others receive a transplant only after relapse or inadequate response. The expected benefit must outweigh the immediate and long term risks. CAR T cell therapy CAR T cell treatment modifies a person's T cells to recognise a target on cancer cells. It is available for selected relapsed or treatment resistant B cell leukaemias, lymphomas and myeloma pathways. It can produce deep responses after other treatment has failed. Possible complications include severe inflammatory reactions and neurological toxicity. Treatment occurs in specialist centres. Radiotherapy Radiotherapy has different roles across blood cancers. It can cure some localised lymphomas or complement chemotherapy. It can treat a bulky lymphoma mass causing local pressure. In myeloma, it can relieve pain or control a threatening bone lesion. It is not the main treatment for dispersed acute leukaemia. Supportive treatment Supportive care is essential during blood cancer treatment. Red cell transfusions treat severe anaemia, while platelet transfusions reduce bleeding risk in selected situations. Antibiotics, antiviral medicines and antifungal treatment prevent or treat infection. Fluids and medicines can protect the kidneys and manage tumour cell breakdown. Supportive treatment can be life saving even though it does not directly remove the cancer. Neutropenic sepsis Chemotherapy and some blood cancers can produce severe neutropenia. A serious infection may then progress rapidly without producing obvious local symptoms. Fever, shaking chills, confusion or sudden severe illness requires immediate contact with the haematology or oncology emergency service. A normal or low temperature does not safely exclude sepsis. Tumour lysis syndrome Rapid destruction of many cancer cells releases their contents into the bloodstream. This can disturb potassium, phosphate, calcium and uric acid levels. Kidney injury, abnormal heart rhythm, seizures or sudden weakness can result. Risk is highest with bulky, rapidly growing cancers and highly effective treatment. Preventive fluids, monitoring and medicines are used when risk is recognised. Severe bleeding in acute leukaemia Low platelets and abnormal clotting can cause serious bleeding. Bleeding into the brain may present with severe headache, vomiting, confusion, weakness or reduced consciousness. One AML subtype, acute promyelocytic leukaemia, is particularly associated with dangerous clotting disruption. Suspected severe bleeding requires emergency hospital care. Leukostasis Extremely high numbers of leukaemia cells can interfere with blood flow through small vessels. This is called leukostasis. Possible features include breathlessness, low oxygen, headache, confusion, visual change or neurological weakness. It is an emergency requiring specialist treatment. The white cell number alone does not fully predict risk because cell properties also matter. Chest pressure and superior vena cava obstruction Lymphoma or ALL can form a large mass within the chest. It may compress the airway or the large vein returning blood from the upper body. Possible features include breathlessness, cough, facial or neck swelling and prominent chest veins. Rapid swelling, noisy breathing or difficulty lying flat requires emergency assessment. Spinal cord compression Myeloma or lymphoma involving the spine can compress the spinal cord or cauda equina. Warning signs include severe progressive back pain, leg weakness and difficulty walking. Numbness around the genitals or buttocks, urinary retention and loss of bowel control are emergencies. Immediate imaging and treatment protect the best chance of preserving movement and continence. Treatment adverse effects Intensive chemotherapy can cause infection, bleeding, mouth ulcers, nausea, hair loss and infertility. Some medicines affect the heart, nerves, lungs, kidneys or liver. Radiotherapy can damage nearby healthy tissue. Transplantation carries immediate and lifelong risks. Treatment plans therefore reflect disease risk, general health and personal priorities. Fertility and pregnancy Chemotherapy, radiotherapy and transplantation can reduce fertility. People who may want biological children should receive fertility information before treatment when time and safety allow. Acute leukaemia sometimes requires treatment too quickly for every preservation option to be practical. Pregnancy during diagnosis requires coordinated haematology, oncology and maternity care. Vaccination and infection prevention Blood cancers and their treatments can weaken immune responses. Vaccination plans may need adjustment before, during or after treatment. Live vaccines can be unsafe during significant immune suppression. Household contacts and preventive medicines may also form part of infection protection. Advice should come from the treating haematology team. Follow up and relapse monitoring Follow up depends on the exact cancer and treatment. Blood counts, molecular tests, scans or marrow tests may monitor response. New symptoms can signal infection, treatment toxicity or relapse. People should use their specialist contact route rather than waiting for a routine appointment when they become unwell. Prognosis varies widely Some acute leukaemias and aggressive lymphomas are curable with intensive treatment. Some chronic leukaemias can be controlled for many years using tablets. Indolent lymphoma can remain stable without treatment but may recur after therapy. Myeloma usually follows a pattern of remission and relapse but treatment options continue to expand. A broad diagnosis such as blood cancer cannot predict one person's future. Emotional and practical effects A rapid leukaemia diagnosis can leave little time to process information before treatment begins. Watch and wait management can create anxiety because cancer remains present without therapy. Treatment may affect work, finances, fertility and family roles. Specialist nurses, psychology, peer support and welfare services can help. What this lesson should not be used for This lesson cannot diagnose blood cancer from fatigue, bruising, a swollen gland or one blood result. A full blood count describes cell numbers but does not establish the cause alone. Do not delay urgent assessment when a laboratory has reported possible acute leukaemia. Do not interpret watch and wait as neglect or assume that every blood cancer requires immediate chemotherapy. Seek emergency help for severe bleeding, breathing difficulty, neurological change, spinal symptoms or severe illness during treatment.

Leukaemia, lymphoma and myeloma are separate blood cancer families requiring different diagnostic tissue and treatment pathways. Acute leukaemia can rapidly cause marrow failure and requires same day specialist assessment once suspected from blood results. Other blood cancers range from indolent disease managed through structured observation to aggressive disease requiring intensive systemic treatment or stem cell transplantation.